Aptar Pharma said today that the European Medicines Agency approved its electronic nasal lockout device, e-Lockout. The device is the 1st and only fully-integrated electronic nasal drug delivery device to be approved by a European regulatory authority, according to the company.
The e-Lockout device is a part of a multi-year development deal with Takeda Pharmaceuticals International (TYO:4502). Aptar agreed to supply its e-Lockout device for use with Takeda’s multi-dose nasal spray version of a fast-acting opioid, Instanyl.
Takeda plans to launch a uni-dose and multi-dose version of its nasal spray with Aptar’s electronic lockout system in Europe.
Get the full story at our sister site, Drug Delivery Business News.
The post Aptar Pharma’s nasal spray compliance device wins EMA nod appeared first on MassDevice.